Showing 51-60 of 454 results
Helsinn Group, the company focused on building quality cancer care, today announces that Helsinn Advanced Synthesis will be exhibiting at the 2014 CPHI Worldwide trade show, which will be held in France at the Paris Nord Villepinte exhibition center, from October 7th-9th 2014.
Helsinn's top management announces that anamorelin, its novel, once-daily ghrelin receiptor agonist significantly increased lean body mass (LBM) compared with placebo in two phase III trials comprising the largest trial program of its kind to date in non-small cell lung cancer patients with cachexia, an area of significant unmet medical need.
Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Delivering Chemotherapy With Confidence: New Strategies to Minimize Treatment-Induced Nausea and Vomiting at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014.
Helsinn Group Receives Positive CHMP Opinion for Akynzeo® (netupitant/palonosetron) for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in the European Union First New Fixed Dose Combination Targeting Two Key Pathways Involved in CINV
The exclusive agreement strengthens the exisitng alliance between the companies in the area of supportive cancer care
Helsinn, the Swiss Group focused on building quality cancer care, today announces the publication of the sustainability report for Helsinn’s Dublin based subsidiary, Helsinn Birex Pharmaceuticals Ltd for the year 2013, in accordance with Global Reporting Initiative (GRI) guidelines.
Helsinn manufacturing achieved a top 10% score in eight buyer perception categories